Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 inhibitors)
Non Small Cell Lung Cancer Recurrent
DRUG: Toripalimab, Anlotinib and Chemotherapy
Progress free survival, Progress free survival is defined as the time from first dose of study treatment until the first date of either disease progression or death due to any cause., until Progressive Disease (PD) or death (up to 24 months)
Objective Response Rate, Objective response rate is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy., each 21 days up to intolerance the toxicity or PD (up to 24 months)|Overall Survival, Overall survival is defined as the time until death due to any cause., from first dose of study treatment until death (up to 24 months)|Disease Control Rate, Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1., each 21 days up to intolerance the toxicity or PD (up to 24 months)
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 inhibitors)